浙江华海药业股份有限公司（以下简称"公司"）5%以上股东周明华先生持 有公司股份总数为 224,418,890 股，占公司总股本的比例为 14.99%。本次部分 股份质押完成后，周明华先生处于质押状态的股份累计数为 93,980,000 股，占 其所持公司股份总数的 41.88%，占公司总股本的比例为 6.28%。 公司于近日收到 5%以上股东周明华先生关于其部分股份质押的通知，现将 具体情况公告如下： | 股东 | 是否为 | 本次质押股 | 是否 | 是否 | | | | 占其所持 | 占公司 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 控股股 | 数 | 为限 | 补充 | 质押起始日 | 质押到期日 | 质权人 | 股份比例 | 总股本 | 质押融资资金用途 | | | 东 | | 售股 | 质押 | | | | | 比例 | | | 周明 华 | 否 | 15,000,000 | 否 | 否 | 2025.8.22 | 至办理解除 质押手续止 | 厦门国际银 行股份有限 公司上海分 | ...

Group 1 - Huahai Pharmaceutical (600521.SH) released its semi-annual report for 2025, showing that as of August 25, 2025, 31 institutional investors disclosed holding A-shares, totaling 144 million shares, which accounts for 9.62% of the total share capital [1] - The top ten institutional investors collectively hold 9.24% of the shares, with a 0.69 percentage point increase compared to the previous quarter [1] Group 2 - In the public fund sector, two funds increased their holdings, including China Europe Medical Health Mixed A and Southern CSI 500 ETF, with an increase ratio of 0.96% [2] - Two public funds decreased their holdings, namely Anxin Medical Health Stock A and Industrial Bank Medical Care A, with a decrease ratio of 0.19% [2] - A total of 22 new public funds were disclosed this period, including Guangda Baodexin Health Superior Mixed A and Huazhang Medical Innovation Mixed A [2] - One social security fund increased its holdings, specifically Guotai Fund Management Co., Ltd. - Social Security Fund 2103 Combination, with an increase ratio of 0.27% [2]

Group 1 - The company reported a total operating revenue of 4,516.35 million yuan, representing a year-on-year decrease of 11.93% [1] - The net profit attributable to shareholders of the listed company was 409.49 million yuan, down 45.30% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 363.42 million yuan, a decline of 52.48% compared to the previous year [1] Group 2 - The company's total R&D investment amounted to 648.76 million yuan, accounting for 14.36% of its operating revenue [1] - R&D investment increased by 23.07% compared to the same period last year [1]

Core Viewpoint - Huahai Pharmaceutical reported a significant decline in both revenue and net profit for H1 2025, primarily due to falling product prices and increased R&D investments [1][2] Financial Performance - H1 revenue reached 4.516 billion yuan, a year-on-year decrease of 11.93% [1] - Net profit attributable to shareholders was 409 million yuan, down 45.30% year-on-year [1] - Non-recurring net profit was 363 million yuan, a decline of 52.48% compared to the previous year [1] - Operating cash flow for H1 was 370 million yuan, a drop of 71.52% year-on-year [2] Reasons for Decline - The decline in net profit is attributed to three main factors: 1. Continuous price drops due to intensified competition and domestic procurement policies, despite an increase in market share [1] 2. Accelerated R&D investments in biological innovation drugs [1] 3. Decreased foreign exchange gains due to currency fluctuations [1] R&D Progress - The product HB0034 (Ruxolitinib injection) has been prioritized for review by the National Medical Products Administration (NMPA) and is expected to be approved for market in Q2 2026 [3] - The key III phase clinical trial for HB0017 for moderate to severe plaque psoriasis is nearing completion, while the trial for ankylosing spondylitis is ongoing [3] - In the oncology pipeline, HB0025 for advanced or recurrent endometrial cancer has submitted a meeting request for confirmatory III phase clinical trials, and significant efficacy data for non-small cell lung cancer will be presented in early September [3]

Core Points - The company held its fourth temporary board meeting of the ninth session on August 25, 2025, with all nine directors present, meeting the legal quorum requirements [1] - The board approved the 2025 semi-annual report and its summary, with a unanimous vote of 9 in favor [2] - The board also approved a special report on the use of raised funds for the first half of 2025, again with a unanimous vote [2] - A resolution was passed for the company's subsidiaries to apply for a total credit limit of up to 1.623 billion yuan from banks, with a maximum term of 5 years [2][3] - The board authorized the management team to handle all credit-related procedures within the approved limit without needing further board approval [3] - The board approved a guarantee for a subsidiary, Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd., for a bank credit limit of up to 205 million yuan [3][5] - The authorization for the guarantee is valid for one year from the date of board approval [3][5]

证券日报网讯 8月25日晚间，华海药业发布公告称，公司于2025年8月25日召开第九届董事会第四次临 时会议，审议通过了《关于公司为下属子公司提供担保议案》，同意公司为下属子公司华海建诚向银行 申请授信额度提供合计不超过2.05亿元（最终以实际发生额为准）的信用担保。 （文章来源：证券日报） ...

Core Viewpoint - Huahai Pharmaceutical (600521) reported a decline in both revenue and net profit for the first half of 2025, primarily due to intensified domestic procurement policies, increased competition in the raw material pharmaceutical industry, and the impact of US-China tariffs [1] Financial Performance - The company achieved an operating revenue of 4.516 billion yuan, a year-on-year decrease of 11.93% [1] - The net profit attributable to shareholders was 409 million yuan, reflecting a year-on-year decline of 45.3% [1] Market Conditions - Despite an increase in market share for major products, continuous price declines negatively impacted sales revenue and profit [1] - The company is accelerating the progress of its biopharmaceutical innovation projects, resulting in a significant year-on-year increase in R&D investment [1] - Foreign exchange rate fluctuations contributed to a decrease in exchange gains compared to the previous year [1]

Group 1 - Company announced a credit guarantee of up to 205 million yuan for its wholly-owned subsidiary Huahai Jiancheng to meet funding needs [1] - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to approximately 3.572 billion yuan, which is 40.15% of the latest audited equity attributable to shareholders [1] - The breakdown of guarantees includes approximately 3.105 billion yuan for subsidiaries (34.89% of the latest audited equity) and 263 million yuan for associated companies (2.95% of the latest audited equity) [1] Group 2 - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34 billion yuan [2]

为进一步优化资金配置，提高财务运营效率，满足下属子公司生产经营和业 务发展需要，公司下属子公司拟向银行申请授信额度（或融资额度）总计不超过 人民币 16.23 亿元（最终以实际发生额为准），授信期限最长不超过 5 年。以上授 信额度不等于公司实际融资金额，具体融资金额将根据运营资金的实际需求确定， 并最终以银行实际审批的授信额度为准。授信有效期内，授信额度可循环使用且 可以在不同银行间进行调剂。为提高工作效率，及时办理融资业务，董事会授权 公司经营管理层或经营管理层转授权相关人士在上述综合授信额度内全权办理授 信相关手续，包括签署相关法律文件等，具体实施事宜无须再另行提交公司董事 会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）于 2025 年 8 月 25 日召开第九届董事会第四次临时会议，审议通过了《关于公司下属子公司 向银行申请综合授信额度的议案》，现将相关事项公告如下： | 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2 ...

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2025-094 号 | | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | 为满足公司下属全资子公司华海建诚在业务发展及建设过程中的资金需求， 公司于 2025 年 8 月 25 日召开第九届董事会第四次临时会议，审议通过了《关于 公司为下属子公司提供担保议案》，同意公司为下属子公司华海建诚向银行申请授 信额度提供合计不超过 2.05 亿元（最终以实际发生额为准）的信用担保。具体情 况如下： 浙江华海药业股份有限公司 关于为子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、担保情况概述 （一）基本情况概述 1 / 4 单位：人民币亿元 担保 方 被担保方 担保方持 股比例 被担保方最 近一期资产 负债率 截至目 前担保 余额 本次新 增担保 额度 新增担保额度占上 市公司最近一期归 属于上市公司股东 的所有者权益的比 担保有 效期 是否关 联担 ...